Evaluation the levels of some hormones in women with polycystic ovary syndrome
Article Sidebar
Main Article Content
Abstract
This study was conducted on 40 Samples of Patients with polycystic ovary syndrome (PCOS) after their diagnosis, The study aimed to identify the most important hormonal disorders associated with this syndrome . The study begins from Octobar 2017 to March 2018 , the age from(19-45) years .Blood samples were taken during the (2-4( days of menstrual cycle and the selected samples were compared with 20 healthy women as control group ,and the following hormones were evaluated Luteninzing hormone (LH), Follicle Stimulating Hormone (FSH), Prolactin (PRL),Testosterone (Testo) and Oxytocin (OX) ,the study showed a high significant in the concentrations of OX ,Testo and LH (P≤0.01) , a high significant in the PRL concentration (P≤0.05) and a high significant in the FSH concentration (P≤0.05(,the results were distributed to three groups according to BMI ,age and treatment, in term BMI it was divided into three groups, BMI(18.5-24.9)(25.0-29.9) (≥30)kg/m2 the results showed a high significant (P≤0.05) in the LH and OX concentration in group BMI (18.5-24.9)kg/m2 and in both PRL and Testo in group BMI(≥30)kg/m2. in term age, it was divided into three groups (19-26) (27-35) (36-45)years, the results showed a high significant (P≤0.05) in LH and Testo concentration at age group (36-45)years ,compared to other groups, and a high significant (P≤0.05) in both PRL and OX, between three group of age , treatment it was divided into three groups of metformin, progesterone contraceptive used and non-used of the treatment .the results showed a high significant (P≤0.05) in LH, PRL, OX and Testo concentrations, and a high significant (P≤0.05) of FSH in women treated compared with non-used
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Lizneva, D. et al. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril, 106: 6-15.
[2] Jalilian, A. et al.(2015). Prevalence of polycystic ovary syndrom and its associated complications in Iranian women: A meta-analysis. Iran Journal Reprod Med,13(10):591-604.
[3] Nardo, L.G.; Patchava , S. and Laing , I. (2008). Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med,50 (4): 267-78.
[4] Sirmans, S.M. and Pate, K.A. (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol, 6: 1–13.
[5] Franks, S. (2009). Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology, 150 (9): 3983-3985.
[6] Sirmans, S.M. and Pate, K.A. )2014). Epidemiology, diagnosis, and management of polycystic ovary syndrome, Clinical epidemiology, 6 -1 pp .
[7] Rotterdam, ESHRE/ASRM-Sponsored, PCOS, Consensus, Workshop, Group.(2004). Revised 2003. Consensus on diagnostic criteria and Long -term health risks related to polycystic ovary syndrome. Fertil. Steril, 81(1): 19-25.
[8] World Health Organization. (2003). Obesity. Preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva.WHO .
[9] Tietz, N. W. (1992).Clinical Guide to Laboratory Tests , 3rd Edition : 22-23 pp.
[10] Berger, P.et al .(1996). Immunochemical mapping of gonadotropins . Moll cell Endocrinol ,125: 33-43.
[11] Braunstein ,G.D. et al . (1978) .First –Trimester Luteinizing Hormone Measurements as an Aid to the Diagnosis of Early Pregnancy Disorders .American Journal of obstetrics and Gynecology , 131: 25-32 .
[12] Fraser , I.S . et al . (1989). Detailed assessment of big Prolactin in women with hyperprolactenemia and normal ovary function. Journal Clin Endo & Metabol , 69 : 585-592.
[13]-Bristow, A.F. (1998). Standardization of protein hormone immunoassays: current controversies. proceeding of the UKNEQAS Endocrinology meeting ACB, 3: 66-73.
[14] Khashie alrrawi .(1984).introduction to statistics. Faculty of Administration and Economics .University of AL Mosul .
[15] Feucer, C.; Barbosa, J. and Dasilva, E.(2014). current insight into gonadotropic pituitary function in the polycystic ovary syndrome .Asian pacific Journal Reproduct ,3(1):64-70 .
[16] Mutib, T.; Hamdan, M. and Al Salihi ,A.F.R. (2014) .INSR gene variation is associated with decreased insulin sensitivity in Iraqi women with PCOs. Iran Journal Reprod Med, 12(7): 499-506.
[17] Kensara, O.A. (2018). prevalence of hypovitaminosis D and its association with hypoadiponectinemia and hyperfollistatinemia ,in Saudi women with nave polycystic ovary syndrome .Journal of clinical &Translational Endocrinology,12 : 20-25.
[18] Ambiger, S.,Patil, S.B, Rekha, M. and Dhananjaya, S.(2017) .Role of leutinizing hormone LH and insulin resistance in polycystic ovarian syndrome .International Journal Reprode contracept obstet Gyncol,6(9):3892-3896 .
[19] Michel ,G. (2002) . Infertility in Women. www. healthadge.com.
[20] Maleki,V .; Izadi ,A, Farsad-Naemi ,A .and Ali Zadeh,M. (2018). Chromium Supplementation does not improve weight loss or metabolic and hormonal variables in patients with polycystic ovary syndrome : a systemic review. Journal Nutrition Research, 56(8):1-10
[21] Olff, M. et al. (2013). The role of oxytocin in social bonding ,stress regulation and mental health :An update on the moderating effects of context and interindividual differences :38(9) 1883-1894.
[22] Ramezanli, F. et al. (2016). Relationships between serum lutinizing hormone level,endometrial thickness and body mass index in polycystic ovary
syndrome patients with and without endometrial hyperplasia .International Journal Fertil Steril,10 (1) :36-41.
[23] Srouji, S.S. et al (2007). pharmacokinetic factors contribute to the inverse Relationship between lutenizing Hormone and Body Mass Index in polycystic ovarian syndrome. Journal Clin Endocrinol metab, 92 : 1347-1352.
[24] Hasan, J.S.; Ali, A.H. and Fakhrildin, M.B. (2015). Role of prolactin in Iraqi obese women with polycystic ovary syndrome, American Journal of medicine and medical sciences ,5(3):135-139 .
[25] Pereira-lima, J.F.S. et al. (2013) .original open Access Hyperprolactinemia and body weight :prevalence of obesity and overweight in patients with hyperprolactinemia. Herbert open Access Journal,1(2):1- 6.
[26] Yuan ,C.et al.(2016) .polycystic ovary syndrome patient with high BMI tend to have functional disorders of androgen excess: aprospective study .Journal of biomedical research , 30 (3) :197-202.
[27] Johromi, B.N.; Dabbaghmanesh, M.H. and Bakhshaei, M.(2018). Assessment of oxytocin level ,glucose metabolism components and cutoff values for oxytocin and anti mullerian hormone in infertile pcos women.Taiwanese Journal of obstetrics and Gynecology ,57(4) :555-559 .
[28] Btevins, J.E .and Ho, J.M. (2013). Role of oxytocin signaling in the regulation of body weight Rev Endocr Metab Disord ,14(4) : 311-29.
[29] Abdallah ,E.B.(2015). study of levels of sex hormones and hormone growth factor is similar to the first insulin in women with polycystic ovary syndrome .MSc thesis.Tikrit,Iraq:150 pp .
[30] Hillier, S.G. (2000). Controlled ovarian stimulation in women. Journal Reprod fertile ,120: 201-10.
[31] Erden, H.F.; Zwain, I.H, Asakura, H. and Yen, S.S.C.(1998).corticotropin – releasing factor inhibits luteinizing hormone-stimulated P450c17 gene expression and androgen production by isolated the thecal cells of human ovarian follicles ,Journal clin Endocrinol Metab, 83: 448.
[32] Goldstein, I.; Meston, C.M, Davis, S. and Traish, A. (2005). womens sexual function and Dysfunction: study Diagnosis andTreatment. CRC Press.pp-205-ISBN 978-1-84214-263-269 .
[33] Velija-Asimi ,Z.(2013). Evaluation of endocrine changes in women with polycystic ovary syndrome during metformin treatment. Bosnian Journal of basic medical sciences ,13(3):180-185.
[34] Lashen ,H. (2010).Role of metaformin in the mangment of polycystic ovary syndrome therapeutic advances in endocrinology and metabolism ,1(3): 117-128 .
[35] Omran, M.Y.(2007).Metformin and polycystic ovary syndrome. International Journal of health science,1(1) : 75-80 .